Zobrazeno 1 - 10
of 315
pro vyhledávání: '"Jimmy J Caudell"'
Autor:
Rebecca A. Bekker, Nina Obertopp, Gage Redler, José Penagaricano, Jimmy J. Caudell, Kosj Yamoah, Shari Pilon-Thomas, Eduardo G. Moros, Heiko Enderling
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-18 (2024)
Abstract Background Tumor-immune interactions shape a developing tumor and its tumor immune microenvironment (TIME) resulting in either well-infiltrated, immunologically inflamed tumor beds, or immune deserts with low levels of infiltration. The pre-
Externí odkaz:
https://doaj.org/article/63c41adfcb5c4541b5077fc9d2aaa211
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionRadiation therapy (RT) is one of the most common anticancer therapies. Yet, current radiation oncology practice does not adapt RT dose for individual patients, despite wide interpatient variability in radiosensitivity and accompanying tre
Externí odkaz:
https://doaj.org/article/69e27a364c274d67b6943ee8c05cc43f
Autor:
Arslan Babar, Neil M. Woody, Ahmed I. Ghanem, Jillian Tsai, Neal E. Dunlap, Matthew Schymick, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku, Joseph Scharpf, Brandon L. Prendes, Nikhil P. Joshi, Jimmy J. Caudell, Farzan Siddiqui, Sandro V. Porceddu, Nancy Lee, Larisa Schwartzman, Shlomo A. Koyfman, David J. Adelstein, Jessica L. Geiger
Publikováno v:
Current Oncology, Vol 28, Iss 4, Pp 2409-2419 (2021)
Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, con
Externí odkaz:
https://doaj.org/article/6936c992016a4b2ca14823b8e16083d3
Autor:
Kamran A. Ahmed, MD, Youngchul Kim, PhD, John A. Arrington, MD, Sungjune Kim, MD, PhD, Michelle DeJesus, BS, Aixa E. Soyano, MD, Avan J. Armaghani, MD, Ricardo L.B. Costa, MD, Hung T. Khong, MD, Loretta S. Loftus, MD, Marilin Rosa, MD, Jimmy J. Caudell, MD, PhD, Roberto Diaz, MD, PhD, Timothy J. Robinson, MD, PhD, Arnold B. Etame, MD, PhD, Nam D. Tran, MD, PhD, Solmaz Sahebjam, MD, Hatem H. Soliman, MD, Brian J. Czerniecki, MD, PhD, Peter A. Forsyth, MD, H. Michael Yu, MD, Hyo S. Han, MD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 6, Pp 100798- (2021)
Purpose: We hypothesize treatment with nivolumab and stereotactic radiosurgery (SRS) will be feasible and well tolerated, and may improve intracranial tumor control rates compared with SRS alone. Methods and Materials: The study was designed as a pro
Externí odkaz:
https://doaj.org/article/d3a069d067ee48fd8facf6e4317a3b58
Autor:
Rathan M. Subramaniam, Lyudmila DeMora, Min Yao, Sue S. Yom, Maura Gillison, Jimmy J. Caudell, John Waldron, Ping Xia, Christine H. Chung, Minh Tam Truong, Michelle Echevarria, Jason W. Chan, Jessica L. Geiger, Loren Mell, Samantha Seaward, Wade L. Thorstad, Jonathan Jay Beitler, Khalil Sultanem, Diagjin Blakaj, Quynh-Thu Le
Publikováno v:
Journal of Nuclear Medicine. 64:362-367
Autor:
Sungjune, Kim, Evan, Wuthrick, Dukagjin, Blakaj, Zeynep, Eroglu, Claire, Verschraegen, Ram, Thapa, Matthew, Mills, Khaled, Dibs, Casey, Liveringhouse, Jeffery, Russell, Jimmy J, Caudell, Ahmad, Tarhini, Joseph, Markowitz, Kari, Kendra, Richard, Wu, Dung-Tsa, Chen, Anders, Berglund, Lauren, Michael, Mia, Aoki, Min-Hsuan, Wang, Imene, Hamaidi, Pingyan, Cheng, Janis, de la Iglesia, Robbert J, Slebos, Christine H, Chung, Todd C, Knepper, Carlos M, Moran-Segura, Jonathan V, Nguyen, Bradford A, Perez, Trevor, Rose, Louis, Harrison, Jane L, Messina, Vernon K, Sondak, Kenneth Y, Tsai, Nikhil I, Khushalani, Andrew S, Brohl
Publikováno v:
The Lancet. 400:1008-1019
Merkel cell carcinoma is among the most aggressive and lethal of primary skin cancers, with a high rate of distant metastasis. Anti-programmed death receptor 1 (anti-PD-1) and programmed death ligand 1 (PD-L1) monotherapy is currently standard of car
Publikováno v:
Bulletin of Mathematical Biology. 85
Fractional calculus has recently been applied to the mathematical modelling of tumour growth, but its use introduces complexities that may not be warranted. Mathematical modelling with differential equations is a standard approach to study and predic
Autor:
Michelle I. Echevarria, George Q. Yang, Dung-Tsa Chen, Kedar Kirtane, Jeffery Russell, Julie Kish, Jameel Muzaffar, Kristen Otto, Tapan Padhya, Caitlin McMullen, Krupal Patel, Christine H. Chung, Jimmy J. Caudell
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics.
Autor:
Jimmy J. Caudell, Maura L. Gillison, Ellie Maghami, Sharon Spencer, David G. Pfister, Douglas Adkins, Andrew C. Birkeland, David M. Brizel, Paul M. Busse, Anthony J. Cmelak, A. Dimitrios Colevas, David W. Eisele, Thomas Galloway, Jessica L. Geiger, Robert I. Haddad, Wesley L. Hicks, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, James W. Rocco, Cristina P. Rodriguez, Panayiotis S. Savvides, David Schwartz, Jatin P. Shah, David Sher, Maie St. John, Randal S. Weber, Gregory Weinstein, Frank Worden, Justine Yang Bruce, Sue S. Yom, Weining Zhen, Jennifer L. Burns, Susan D. Darlow
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:224-234
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The s
Autor:
Jimmy J. Caudell, Pedro A. Torres-Saavedra, David I. Rosenthal, Rita S. Axelrod, Phuc Felix Nguyen-Tan, Eric J. Sherman, Randal S. Weber, James M. Galvin, Adel K. El-Naggar, Andre A. Konski, Michelle I. Echevarria, Neal E. Dunlap, George Shenouda, Anurag K. Singh, Jonathan J. Beitler, Adam Garsa, James A. Bonner, Adam S. Garden, Ozer Algan, Jonathan Harris, Quynh-Thu Le
Publikováno v:
Int J Radiat Oncol Biol Phys
PURPOSE: The combination of cisplatin and radiation or cetuximab and radiation improves overall survival of patients with locoregionally advanced head and neck carcinoma. NRG Oncology conducted a phase 3 trial to test the hypothesis that adding cetux